Your A1C is an average of your blood sugar over 2–3 months, and an important measure of how your type 2 diabetes treatment is going. And in adults with type 2 diabetes who also have known heart disease, JARDIANCE, one of the medicines in TRIJARDY XR, can reduce the risk of cardiovascular death. TRIJARDY XR combines 3 diabetes medications-JARDIANCE (empagliflozin), TRADJENTA (linagliptin), and metformin hydrochloride, working together to lower A1C, along with diet and exercise. Type 2 diabetes can make it hard to control your A1C-it may be time for a medication that works in multiple ways. TRIJARDY XR contains the benefits of 3 medications: Learn more about TRIJARDY XR TRIJARDY XR can help lower your A1C
If you have had pancreatitis (inflammation of the pancreas) in the past, it is not known if you have a higher chance of getting pancreatitis while you take TRIJARDY XR.
It may increase their risk of diabetic ketoacidosis (increased ketones in the blood or urine).
JANUMET COPAY CARD UPDATE
Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.3-in-1 TRIJARDY XR may give you a chance of lowering your A1C The company assumes no duty to update the information to reflect subsequent developments. The information contained in this website was current as of the date presented. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2021 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (No Duty to Update The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Risks and uncertainties include but are not limited to, general industry conditions and competition general economic factors, including interest rate and currency exchange rate fluctuations the impact of the recent global outbreak of novel coronavirus disease (COVID-19) the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally global trends toward health care cost containment technological advances, new products and patents attained by competitors challenges inherent in new product development, including obtaining regulatory approval the company’s ability to accurately predict future market conditions manufacturing difficulties or delays financial instability of international economies and sovereign risk dependence on the effectiveness of the company’s patents and other protections for innovative products and the exposure to litigation, including patent litigation, and/or regulatory actions. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties.
Private Securities Litigation Reform Act of 1995. This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
0 kommentar(er)
